The results of a Phase III study (in patients with type 2 diabetes) designed to evaluate whether MannKind Corporation (Nasdaq: MNKD)’s Technosphere® Insulin System showed similar safety and efficacy compared to patients treated with insulin aspart (NovoLog®), an injected rapid-acting insulin analog (RAA), was presented at the 42nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Copenhagen last September 16, 2006.
According to Dr. Peter Richardson, Chief Scientific Officer of MannKind:
"This study demonstrated that patients with Type 2 diabetes using Technosphere® Insulin achieved comparable improvements in glycemic control (HbA1c) to patients treated with an injected RAA.
In addition, we observed no adverse effect on pulmonary function in either treatment group. However, unlike the injected RAA group, Technosphere® Insulin patients lost weight during the treatment period.”
The Technosphere® Insulin System is MannKind Corp.’s lead investigational product for diabetes, whose phase III pivotal studies are suggesting that this could be the next pulmonary insulin product to reach the market, as stated by Alfred Mann, Chairman of the Board and Chief Executive Officer of MannKind.
More details from the press release.
Comment Preview